Evidence map›Paper›PMID 42442753›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

A Clinical Case of Treatment-Emergent Acinetobacter baumannii Non-Susceptibility to Sulbactam-Durlobactam.

Sima L Sharara, Lorena Diaz, Tomefa E Asempa, Jose R W Martinez, Nicolas Canales, Yehudit Bergman, Shannon G Murphy, Sara M Karaba, Andrew E Clark, Daniel V Zurawski and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sima L ShararaJohns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-9404-0454
Lorena DiazUniversidad del Desarrollo, Santiago, Chile.
Tomefa E AsempaCenter for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
Jose R W MartinezUniversidad del Desarrollo, Santiago, Chile.
Nicolas CanalesUniversidad del Desarrollo, Santiago, Chile.
Yehudit BergmanJohns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-4262-7173
Shannon G MurphyJohns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0003-4544-1400
Sara M KarabaJohns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0001-8452-5549
Andrew E ClarkJohns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-0722-0482
Daniel V ZurawskiCenter for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
Sara E CosgroveJohns Hopkins University, Baltimore, Maryland, USA.
Patricia J SimnerMayo Clinic, Rochester, Minnesota, USA.
Jose M MunitaUniversidad del Desarrollo, Santiago, Chile.ORCID 0000-0002-7870-1056
Pranita D TammaJohns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-4143-6324

Funding

RESEARCH TRAINING IN MICROBIAL DISEASEST32AI007291 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JOEL N BLANKSON, Sara Elizabeth Cosgrove · 1986 to 2026
$9.1M
Advancing Mentorship at the Johns Hopkins Integrated Center for Combating Antimicrobial Resistant BacteriaK24AI185302 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Pranita Tamma · 2025 to 2026
$416k
Integrating Genomic and Clinical Approaches to Define and Prevent Cefiderocol Resistance in Carbapenem-Resistant OrganismsK23AI201893 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SIMA LYNN SHARARA · 2026 to 2026
$196k
NIAID NIH HHS K23 AI201893NIAID NIH HHS K24 AI185302NIAID NIH HHS T32 AI007291
6 · The paper itself

Abstract

We report an eightfold increase in sulbactam-durlobactam MICs in a carbapenem-resistant Acinetobacter baumannii cerebrospinal fluid isolate recovered after 14 days of sulbactam-durlobactam plus meropenem therapy. Treatment-emergent mutations in the AdeFGH efflux system were identified, accompanied by a 166-fold increase in adeG expression. Efflux pump inhibition restored sulbactam-durlobactam susceptibility.

Indexed as

antimicrobial resistancecefiderocolCRABPBPsulbactam-durlobactam

Identifiers

PMID42442753
PMCPMC13579459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.